RxDoctor Payments Data

Solibe Ufondu, MD

Family Medicine · East Stroudsburg, PANPI 1548232523

Payments from drug & device makers

$3,643in general payments, 2019–2025

Across 179 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$940
  • Exact Sciences$395
  • AstraZeneca$321
  • Amgen$318
  • Pfizer$199
  • Boehringer Ingelheim$197
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,10185%
  • Education$54215%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,643 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$87,903
Medicare patients
202
Services billed
904

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin15$19,455
TradjentaLinagliptin16$19,106
EliquisApixaban29$17,202
JanuviaSitagliptin Phosphate13$7,889
Varenicline Tartrate14$4,213
Lidocaine23$3,479
Atorvastatin Calcium206$3,329
Albuterol Sulfate HfaAlbuterol Sulfate78$2,954
Amlodipine Besylate321$2,758
Ventolin HfaAlbuterol Sulfate14$1,862
Baclofen54$1,853
Memantine Hcl13$1,691
Metoprolol Succinate84$1,613
Fluticasone Propionate57$1,531
Duloxetine Hcl26$1,398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$197$38,56131 claims
PfizerEliquis$199$17,20229 claims
MerckJanuvia$116$7,88913 claims
Scilex Pharmaceuticals Inc.Colchicine$27$1,30014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in East Stroudsburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →